[go: up one dir, main page]

NO2947086T3 - - Google Patents

Info

Publication number
NO2947086T3
NO2947086T3 NO14836782A NO14836782A NO2947086T3 NO 2947086 T3 NO2947086 T3 NO 2947086T3 NO 14836782 A NO14836782 A NO 14836782A NO 14836782 A NO14836782 A NO 14836782A NO 2947086 T3 NO2947086 T3 NO 2947086T3
Authority
NO
Norway
Application number
NO14836782A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2947086T3 publication Critical patent/NO2947086T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO14836782A 2013-08-12 2014-08-11 NO2947086T3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013167600 2013-08-12
PCT/JP2014/071158 WO2015022926A1 (fr) 2013-08-12 2014-08-11 Nouveau composé pyrimidine fusionnée ou son sel

Publications (1)

Publication Number Publication Date
NO2947086T3 true NO2947086T3 (fr) 2018-06-02

Family

ID=52468312

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14836782A NO2947086T3 (fr) 2013-08-12 2014-08-11

Country Status (22)

Country Link
US (1) US9580432B2 (fr)
EP (1) EP2947086B1 (fr)
JP (1) JP6035423B2 (fr)
KR (1) KR101828187B1 (fr)
CN (1) CN105452257B (fr)
AU (1) AU2014307437B2 (fr)
BR (1) BR112016002069B1 (fr)
CA (1) CA2921208C (fr)
DK (1) DK2947086T3 (fr)
ES (1) ES2661733T3 (fr)
HU (1) HUE036834T2 (fr)
MX (1) MX360498B (fr)
MY (1) MY171831A (fr)
NO (1) NO2947086T3 (fr)
PH (1) PH12015502737B1 (fr)
PL (1) PL2947086T3 (fr)
PT (1) PT2947086T (fr)
RU (1) RU2666349C2 (fr)
SG (1) SG11201600048VA (fr)
TR (1) TR201802875T4 (fr)
TW (1) TWI585089B (fr)
WO (1) WO2015022926A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014308616B2 (en) 2013-08-23 2018-12-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2016213030B2 (en) * 2015-01-30 2019-01-31 Taiho Pharmaceutical Co., Ltd. Preventive and/or therapeutic agent of immune disease
JP6093486B2 (ja) 2015-01-30 2017-03-08 大鵬薬品工業株式会社 縮合ピリミジン化合物の新規な塩及びその結晶
DK3345907T3 (da) * 2015-09-01 2020-06-22 Taiho Pharmaceutical Co Ltd Pyrazolo[3,4-d]pyrimidinforbindelser eller salte deraf
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
TWI642671B (zh) * 2015-10-28 2018-12-01 台灣神隆股份有限公司 依魯替尼之製備方法及其中間體
EP3269370B1 (fr) 2016-02-23 2020-01-08 Taiho Pharmaceutical Co., Ltd. Nouveau composé pyrimidine condensé ou sel de celui-ci
EP4006035B1 (fr) * 2016-08-15 2023-11-22 Neupharma, Inc. Dérivés de quinazoline en tant qu'inhibiteurs de la tyrosine kinase pour le traitement du cancer
WO2018159613A1 (fr) * 2017-02-28 2018-09-07 大鵬薬品工業株式会社 Activateur d'effet antitumoral utilisant un composé pyrazolo[3,4-d]pyrimidine
MY201941A (en) 2017-08-21 2024-03-25 Taiho Pharmaceutical Co Ltd Fusion protein of dctn1 protein with ret protein
PT3909584T (pt) * 2019-01-11 2024-01-12 Taiho Pharmaceutical Co Ltd Composto de pirimidina ou um seu sal
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
TWI895316B (zh) * 2019-12-19 2025-09-01 日商大鵬藥品工業股份有限公司 以縮合嘧啶化合物作為有效成分之治療劑
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
KR20230031926A (ko) * 2020-07-15 2023-03-07 다이호야쿠힌고교 가부시키가이샤 종양의 치료에 사용되는 피리미딘 화합물을 포함하는 조합
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN114736207B (zh) * 2022-04-28 2023-03-31 武汉九州钰民医药科技有限公司 一种小分子her2抑制剂的制备工艺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157434B2 (en) 2003-10-27 2007-01-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CN101336244B (zh) 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物
EA200870385A1 (ru) 2006-03-29 2009-04-28 Фолдркс Фармасьютикалз, Инк. Ингибирование токсичности альфа-синуклеина
EP2089391B1 (fr) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Sonde d'activité de la tyrosine kinase de bruton et son procédé d'utilisation
SG10202107066WA (en) 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
JP2009235057A (ja) * 2007-10-31 2009-10-15 Santen Pharmaceut Co Ltd 血管新生阻害活性を有する新規インドール誘導体
EP2361248B1 (fr) 2008-06-27 2018-09-19 Celgene CAR LLC Composés hétéro-aryles et leurs utilisations
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
PH12014500122A1 (en) 2011-07-13 2014-03-24 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US9586009B2 (en) * 2011-07-15 2017-03-07 Sanofi-Aventis Deutschland Gmbh Drug delivery device
CN103958512B (zh) * 2012-01-19 2016-01-20 大鹏药品工业株式会社 3,5-双取代炔基苯化合物及其盐
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途

Also Published As

Publication number Publication date
PH12015502737A1 (en) 2016-03-07
JP6035423B2 (ja) 2016-11-30
US20160115168A1 (en) 2016-04-28
TW201536786A (zh) 2015-10-01
TWI585089B (zh) 2017-06-01
ES2661733T3 (es) 2018-04-03
PT2947086T (pt) 2018-03-09
WO2015022926A1 (fr) 2015-02-19
RU2015156524A (ru) 2017-09-14
MX2016001845A (es) 2016-05-16
EP2947086B1 (fr) 2018-01-03
CA2921208C (fr) 2018-02-20
PL2947086T3 (pl) 2018-06-29
AU2014307437B2 (en) 2016-12-15
CA2921208A1 (fr) 2015-02-19
SG11201600048VA (en) 2016-03-30
PH12015502737B1 (en) 2018-08-31
US9580432B2 (en) 2017-02-28
AU2014307437A1 (en) 2016-01-21
HUE036834T2 (hu) 2018-08-28
JPWO2015022926A1 (ja) 2017-03-02
CN105452257A (zh) 2016-03-30
TR201802875T4 (tr) 2018-03-21
EP2947086A1 (fr) 2015-11-25
HK1217703A1 (zh) 2017-01-20
MY171831A (en) 2019-11-01
KR20160038891A (ko) 2016-04-07
RU2666349C2 (ru) 2018-09-07
KR101828187B1 (ko) 2018-02-09
MX360498B (es) 2018-11-05
BR112016002069A2 (pt) 2017-08-01
BR112016002069B1 (pt) 2020-08-18
CN105452257B (zh) 2017-09-05
EP2947086A4 (fr) 2016-06-22
DK2947086T3 (en) 2018-03-19

Similar Documents

Publication Publication Date Title
AP2016009275A0 (fr)
BR112015007533A2 (fr)
BR102016010778A2 (fr)
BR112014017733A2 (fr)
BR112014018502A2 (fr)
BR112014017739A2 (fr)
BR112014019326A2 (fr)
BR112014018480A2 (fr)
BR112014018516A2 (fr)
BR112014020341A2 (fr)
BR112014017855A2 (fr)
BR112014017765A2 (fr)
BR112014017669A2 (fr)
BR112014021878A2 (fr)
BR112014018468A2 (fr)
BR112014017901A2 (fr)
BR112014019204A2 (fr)
BR112014018207A2 (fr)
BR112015015948A2 (fr)
BR112014017722A2 (fr)
BR112014017653A2 (fr)
BR112014018578A2 (fr)
BR112014018483A2 (fr)
BR112014017794A2 (fr)
BR112014017601A2 (fr)